Brief: AFT Pharmaceuticals Starts To License Maxigesic IV With Deal In South Korea
05/11/2018 20:44
Nov 6 (Reuters) - Aft Pharmaceuticals Ltd AFT.NZ :
* STARTED COMMERCIALIZATION PROGRAM FOR PATENTED MAXIGESIC
INTRAVENOUS (IV) FORMULATION THROUGH DEAL IN SOUTH KOREA
Source: https://bit.ly/2D2XK6m
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyongbo Pharmaceutical
See all newsBrief: Kyongbo Pharmaceutical Q1 Operating Profit 713 Million Won, Up 489.3% From Year Earlier
Brief: Kyongbo Pharmaceutical Q3 Operating Profit 474 Million Won, Down 85% From Year Earlier
Brief: Kyongbo Pharmaceutical Q2 Operating Profit 2.4 Billion Won, Up 90% From Year Earlier
Brief: Kyongbo Pharmaceutical To Invest 85.5 Billion Won In Building Additional Factory
Brief: Kyongbo Pharmaceutical Q2 Operating Profit 1.3 Billion Won, Down 14.8% From Year Earlier